370 related articles for article (PubMed ID: 30675694)
21. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction.
Mai I; Bauer S; Perloff ES; Johne A; Uehleke B; Frank B; Budde K; Roots I
Clin Pharmacol Ther; 2004 Oct; 76(4):330-40. PubMed ID: 15470332
[TBL] [Abstract][Full Text] [Related]
22. Clinical relevance of St. John's wort drug interactions revisited.
Nicolussi S; Drewe J; Butterweck V; Meyer Zu Schwabedissen HE
Br J Pharmacol; 2020 Mar; 177(6):1212-1226. PubMed ID: 31742659
[TBL] [Abstract][Full Text] [Related]
23. The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype.
Markert C; Kastner IM; Hellwig R; Kalafut P; Schweizer Y; Hoffmann MM; Burhenne J; Weiss J; Mikus G; Haefeli WE
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):423-8. PubMed ID: 25286744
[TBL] [Abstract][Full Text] [Related]
24. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials.
Whitten DL; Myers SP; Hawrelak JA; Wohlmuth H
Br J Clin Pharmacol; 2006 Nov; 62(5):512-26. PubMed ID: 17010103
[TBL] [Abstract][Full Text] [Related]
25. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
26. St John's wort, a herbal antidepressant, activates the steroid X receptor.
Wentworth JM; Agostini M; Love J; Schwabe JW; Chatterjee VK
J Endocrinol; 2000 Sep; 166(3):R11-6. PubMed ID: 10974665
[TBL] [Abstract][Full Text] [Related]
27. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
[TBL] [Abstract][Full Text] [Related]
28. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.
Wang LS; Zhou G; Zhu B; Wu J; Wang JG; Abd El-Aty AM; Li T; Liu J; Yang TL; Wang D; Zhong XY; Zhou HH
Clin Pharmacol Ther; 2004 Mar; 75(3):191-7. PubMed ID: 15001970
[TBL] [Abstract][Full Text] [Related]
29. Clinical drugs that interact with St. John's wort and implication in drug development.
Di YM; Li CG; Xue CC; Zhou SF
Curr Pharm Des; 2008; 14(17):1723-42. PubMed ID: 18673195
[TBL] [Abstract][Full Text] [Related]
30. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
31. Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Wu F; Krishna G; Surapaneni S
Cancer Chemother Pharmacol; 2020 Oct; 86(4):461-473. PubMed ID: 32886148
[TBL] [Abstract][Full Text] [Related]
32. St. John's wort (Hypericum perforatum) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants.
Klier CM; Schmid-Siegel B; Schäfer MR; Lenz G; Saria A; Lee A; Zernig G
J Clin Psychiatry; 2006 Feb; 67(2):305-9. PubMed ID: 16566628
[TBL] [Abstract][Full Text] [Related]
33. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.
Moore LB; Goodwin B; Jones SA; Wisely GB; Serabjit-Singh CJ; Willson TM; Collins JL; Kliewer SA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7500-2. PubMed ID: 10852961
[TBL] [Abstract][Full Text] [Related]
34. Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence.
Izzo AA
Int J Clin Pharmacol Ther; 2004 Mar; 42(3):139-48. PubMed ID: 15049433
[TBL] [Abstract][Full Text] [Related]
35. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.
Obach RS
J Pharmacol Exp Ther; 2000 Jul; 294(1):88-95. PubMed ID: 10871299
[TBL] [Abstract][Full Text] [Related]
37. The recovery time-course of CYP3A after induction by St John's wort administration.
Imai H; Kotegawa T; Tsutsumi K; Morimoto T; Eshima N; Nakano S; Ohashi K
Br J Clin Pharmacol; 2008 May; 65(5):701-7. PubMed ID: 18294328
[TBL] [Abstract][Full Text] [Related]
38. Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach.
Adiwidjaja J; Boddy AV; McLachlan AJ
Br J Clin Pharmacol; 2020 Oct; 86(10):2080-2094. PubMed ID: 32250458
[TBL] [Abstract][Full Text] [Related]
39. Drug interactions with St John's wort : mechanisms and clinical implications.
Mannel M
Drug Saf; 2004; 27(11):773-97. PubMed ID: 15350151
[TBL] [Abstract][Full Text] [Related]
40. Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided.
Huppertz A; Werntz L; Meid AD; Foerster KI; Burhenne J; Czock D; Mikus G; Haefeli WE
Br J Clin Pharmacol; 2018 Dec; 84(12):2903-2913. PubMed ID: 30192025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
